Assessment of pharmacokinetic drug-drug interaction between pradigastat and acetaminophen in healthy subjects

Ayalasomayajula, Surya; Meyers, Dan; Koo, Phillip J.; Salunke, Atish; Majumdar, Tapan; Rebello, Sam; Sunkara, Gangadhar; Chen, Jin

doi:10.1007/s00228-015-1822-2

“…For its part, Carrasco-Portugal et al, [22] demonstrated a lack influence of hyoscine butylbromide (20 mg) on the oral pharmacokinetics of ketorolac (10 mg) when were administered in an oral fixed dose formulation. Similarly to our results, Ajima et al, [23] demonstrated a significantly effect of hyoscine butylbromide on the bioavailability of paracetamol (which has been demonstrated to be a marker of gastric emptying/motility [24]). Previous to the administration of an oral dose of parecetamol (1 g), an oral dose of hyoscine butylbromide (10 mg) was administered.…”

Section: Resultssupporting

confidence: 92%

Evaluation of the Influence of Hyoscine Butylbromide on the Oral Bioavailability of Lansoprazole in Healthy Adult Volunteers

et al. 2016

View full text Add to dashboard Cite

The gastroesophageal reflux and/or peptic ulcer diseases are clinical conditions that occur usually accompanied of symptomatic pain. Lansoprazole, a proton pump inhibitor class drug is widely used in clinical practice for treatment of these diseases. However, its efficacy can be improved by combining with spasmolytic and/or visceral analgesic such as hyoscine butylbromide. Since hyoscine butylbromide is barely absorbed and exerts some local effects at gastrointestinal tract which may modify the absorption of lansoprazole, it is important to establish if there is a pharmacokinetic interaction after the oral concomitant administration of both drugs. For this objective, twenty-five subjects received under a crossover design an oral administration of lansoprazole (15 mg) plus placebo or a fixed-dose combination with hyoscine butiylbromide (15 mg + 10 mg, respectively). Plasma samples were obtained at different times during 10 hours. Lansoprazole plasma concentrations were determined by a high performance liquid chromatography method coupled to tandem mass spectrometry. Fixed-dose combination was well tolerated. Lansoprazole pharmacokinetic parameters were: Cmax 621.81 ± 212.79 and 450.38 ± 192.14 ng/mL; AUC 0−t 1941.36 ± 845.57 and 1454.66 ± 757.28 ng•h/mL; t max 2.83 ± 0.99 and 3.40 ± 1.82h; t 1/2 1.35 ± 0.39 and 1.45 ± 0.51 h, for alone and combined fixed-dose formulation, respectively. Pharmacokinetic parameters were compared by analysis of variance and ratios of AUC 0−t , C max and 90% confidence intervals * Corresponding author. N. Santos-Caballero et al. 265 obtained. Since confidence intervals exceed the 80%-125% limits for these parameters, we conclude that there is a significantly pharmacokinetic interaction of lansoprazole when it is administered concomitantly with hyoscine butylbromide.

show abstract

“…Acetaminophen has a high permeability and high solubility and hence it is preferably employed to study gastric emptying properties of drugs. 8 The absorption of Acetaminophen was delayed by the concomitant administration of Exenatide, 9 Liraglutide 10 or Lixisenatide. 11 The interaction between Acetaminophen and GLP-1 agonists is minimal and clinically insignificant and no management required.…”

Section: Acetaminophen (Paracetamol)mentioning

confidence: 99%

Pharmacologically relevant drug interactions of Glucagon-like peptide-1 receptor agonists

Maideen¹

2019

JAPLR

View full text Add to dashboard Cite

Glucagon-like peptide-1 receptor agonists are incretin mimetics and they help to manage the blood glucose of patients with type 2 diabetes mellitus. The gastric emptying is delayed by the administration of Glucagon-like peptide-1 receptor agonists and hence the absorption of orally administered medications such as Acetaminophen, Digoxin, Warfarin, Oral contraceptive pills, Metformin, Statins, Angiotensin Converting Enzyme Inhibitors and Griseofulvin delayed by their concomitant use. It has been observed that the pharmacokinetics of all these drugs did not get altered by the concurrent administration of Glucagon-like peptide-1 receptor agonists. Moreover, the delay in absorption of interacting drugs could be avoided by taking 1 hour before the administration of Glucagon-like peptide-1 receptor agonists.

show abstract

“…Acetaminophen has a high permeability and high solubility and hence it is preferably employed to study gastric emptying properties of drugs. 8 The absorption of Acetaminophen was delayed by the concomitant administration of Exenatide, 9 Liraglutide 10 or Lixisenatide. 11 The interaction between Acetaminophen and GLP-1 agonists is minimal and clinically insignificant and no management required.…”

Section: Acetaminophen (Paracetamol)mentioning

confidence: 99%

Pharmacologically relevant drug interactions of Glucagon-like peptide-1 receptor agonists

Maideen¹

2019

JAPLR

7

0

View full text Add to dashboard Cite

Glucagon-like peptide-1 receptor agonists are incretin mimetics and they help to manage the blood glucose of patients with type 2 diabetes mellitus. The gastric emptying is delayed by the administration of Glucagon-like peptide-1 receptor agonists and hence the absorption of orally administered medications such as Acetaminophen, Digoxin, Warfarin, Oral contraceptive pills, Metformin, Statins, Angiotensin Converting Enzyme Inhibitors and Griseofulvin delayed by their concomitant use. It has been observed that the pharmacokinetics of all these drugs did not get altered by the concurrent administration of Glucagon-like peptide-1 receptor agonists. Moreover, the delay in absorption of interacting drugs could be avoided by taking 1 hour before the administration of Glucagon-like peptide-1 receptor agonists.

show abstract

Assessment of pharmacokinetic drug-drug interaction between pradigastat and acetaminophen in healthy subjects

Abstract: In the presence of steady-state pradigastat, the pharmacokinetics of acetaminophen is unchanged, when given before, with, or 3 h after a meal. However, when given 1 h after a meal, the Tmax of acetaminophen was delayed by ∼1.25 h without affecting Cmax or AUC.

Cited by 7 publications

References 13 publications

Evaluation of the Influence of Hyoscine Butylbromide on the Oral Bioavailability of Lansoprazole in Healthy Adult Volunteers

Evaluation of the Influence of Hyoscine Butylbromide on the Oral Bioavailability of Lansoprazole in Healthy Adult Volunteers

Pharmacologically relevant drug interactions of Glucagon-like peptide-1 receptor agonists

Pharmacologically relevant drug interactions of Glucagon-like peptide-1 receptor agonists

Contact Info

Product

Resources

About